徐潇雨

Cooley advised biotechnology company Keymed Biosciences on its HK$3.1 billion (US$400 million) initial public offering on the Hong Kong Stock Exchange. Partners Yiming Liu, Michael Yu and Will Cai led the Cooley team advising Keymed Biosciences on its public debut, which also included Yiying Wang, Xiaoyu Xu, Kaiting Yang, Henry Wang, Bridget Wang and Iris Yang.

Cooley advised ImmuneOnco Biopharmaceuticals, a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies, on its HK$319 million initial public offering.

Cooley advised China International Capital Corporation Hong Kong Securities Limited (CICC) and other underwriters on Laekna’s HK$791 million (US$101 million) initial public offering of 63,728,000 shares on the Hong Kong Stock Exchange, the largest 18A offering year to date.

Cooley advised IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer innovative drugs based on synthetic lethality on its license and collaboration agreement with Eikon Therapeutics, a biotechnology company.